Summary
AKRO Chart
My Top 3 Pharma Stocks
Obesity, type 2 diabetes, and cancer continue to grow across the globe, but pharma stocks remain off the radars of many investors. Many of them consistently beat the Street's consensus estimates and offer dividend yields even higher than IT, as well as oil and gas stocks. In this article, I reveal my top 3 Big Pharma players.
Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug
Novo Nordisk said on Thursday it would buy U.S.-based Akero Therapeutics for up to $5.2 billion to add its promising experimental liver disease drug, in the first major deal by the Danish drugmaker's new CEO to boost growth.
Novo Nordisk To Buy Akero Therapeutics for $4.7 Billion
Novo said the acquisition of would contribute to its strategy to develop medicines for people living with diabetes, obesity and their associated comorbidities.
Akero Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| SY Sharon York Springhill Fund Asset Management (HK) Co. Ltd. | 19,925 | $554,313.5 | $554,313.5 | - | - |
| VT Vincent Tortorella Point72 (DIFC) Ltd | 3,693 | $175,328 | $175,343.64 | $15.64 | 0.01% |
Akero Therapeutics, Inc. (AKRO) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Akero Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Andrew Cheng CEO | NASDAQ (NGS) Exchange | 00973Y108 CUSIP |
| US Country | 69 Employees | - Last Dividend | - Last Split | 20 Jun 2019 IPO Date |
Overview
Akero Therapeutics, Inc., initially known as Pippin Pharmaceuticals, Inc., rebranded itself in May 2018. Established in 2017 and based in South San Francisco, California, the company, along with its subsidiary, dedicates its efforts to innovating treatments aimed at serious metabolic diseases prevalent in the United States. Through its strategic license agreement with Amgen Inc., Akero Therapeutics has positioned itself as a notable entity in the development, manufacturing, distribution, and sales of novel treatments specifically designed for metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH) and other related conditions.
Products and Services
- Efruxifermin (EFX)
Akero Therapeutics' flagship product, efruxifermin (EFX), represents a significant advancement in the treatment of metabolic diseases. Currently in Phase 3 clinical trials, EFX is a pioneering therapy designed to protect against cellular stress while concurrently regulating the metabolism of lipids, carbohydrates, and proteins across the body. The primary focus of EFX is the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. Its development and potential distribution have been made possible through a substantial license agreement with Amgen Inc., acknowledging EFX's prospective impact on MASH and other metabolic diseases.
